MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317753 | Name: Doxylamine Succinate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Doxylamine Succinate is a pyridine histamine H1 antagonist with pronounced sedative properties. Doxylamine succinate competitively blocks the histamine H1 receptor and limits the typical allergic and anaphylactic responses, including bronchoconstriction, vasodilation, increased capillary permeability, and spasmodic contraction of gastrointestinal smooth muscle, caused by actions of histamine on bronchial and gastrointestinal smooth muscles, and on capillaries. This drug also prevents histamine-induced pain and itching of the skin and mucous membranes.

Chemical Structure

Doxylamine Succinate
Doxylamine Succinate
CAS#562-10-7 (succinate)

Theoretical Analysis

MedKoo Cat#: 317753

Name: Doxylamine Succinate

CAS#: 562-10-7 (succinate)

Chemical Formula: C21H28N2O5

Exact Mass: 0.0000

Molecular Weight: 388.46

Elemental Analysis: C, 64.93; H, 7.27; N, 7.21; O, 20.59

Price and Availability

Size Price Availability Quantity
1g USD 250.00 2 weeks
5g USD 550.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
469-21-6 (free base) 562-10-7 (succinate)
Synonym
Doxylamine Succinate; Decapryn; Unisom; Evigoa D; Gittalun; NSC-74772; NSC74772; NSC 74772
IUPAC/Chemical Name
N,N-dimethyl-2-(1-phenyl-1-(pyridin-2-yl)ethoxy)ethan-1-amine succinate
InChi Key
KBAUFVUYFNWQFM-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H22N2O.C4H6O4/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16;5-3(6)1-2-4(7)8/h4-12H,13-14H2,1-3H3;1-2H2,(H,5,6)(H,7,8)
SMILES Code
CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C.C(CC(=O)O)C(=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Doxylamine (succinate), a first generation antihistamine, is a histamine (H1) receptor antagonist.
In vitro activity:
TBD
In vivo activity:
TBD
Solvent mg/mL mM
Solubility
DMF 25.0 64.36
DMSO 67.7 174.19
Ethanol 41.5 106.83
PBS (pH 7.2) 10.0 0.26
Water 64.0 164.75
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 388.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
TBD
In vitro protocol:
TBD
In vivo protocol:
TBD
1: Pope E, Maltepe C, Koren G. Comparing pyridoxine and doxylamine succinate-pyridoxine HCl for nausea and vomiting of pregnancy: A matched, controlled cohort study. J Clin Pharmacol. 2015 Jul;55(7):809-14. doi: 10.1002/jcph.480. Epub 2015 Mar 27. PubMed PMID: 25663469. 2: Nuangchamnong N, Niebyl J. Doxylamine succinate-pyridoxine hydrochloride (Diclegis) for the management of nausea and vomiting in pregnancy: an overview. Int J Womens Health. 2014 Apr 12;6:401-9. doi: 10.2147/IJWH.S46653. eCollection 2014. Review. PubMed PMID: 24748822; PubMed Central PMCID: PMC3990370. 3: Koren G, Vranderick M, Gill SK, Macleod S. Sex differences in the pharmacokinetics and bioequivalence of the delayed-release combination of doxylamine succinate-pyridoxine hydrochloride; implications for pharmacotherapy in pregnancy. J Clin Pharmacol. 2013 Dec;53(12):1268-76. doi: 10.1002/jcph.184. Epub 2013 Oct 10. PubMed PMID: 24123059. 4: Cada DJ, Demaris K, Levien TL, Baker DE. Doxylamine succinate/pyridoxine hydrochloride. Hosp Pharm. 2013 Oct;48(9):762-6. doi: 10.1310/hpj4809-762. PubMed PMID: 24421551; PubMed Central PMCID: PMC3857125. 5: Nulman I, Koren G. Pharmacokinetic comparison of a delayed-release combination of doxylamine succinate and pyridoxine hydrocholoride (Diclectin) and oral solutions of these drugs in healthy women of childbearing age. Can J Clin Pharmacol. 2009 Fall;16(3):e400-6. Epub 2009 Oct 29. PubMed PMID: 19923636. 6: Pathak A, Rajput SJ. Simultaneous determination of a ternary mixture of doxylamine succinate, pyridoxine hydrochloride, and folic acid by the ratio spectra-zero-crossing, double divisor-ratio spectra derivative, and column high-performance liquid chromatographic methods. J AOAC Int. 2008 Sep-Oct;91(5):1059-69. PubMed PMID: 18980119. 7: Somashekar BS, Nagana Gowda GA, Ramesha AR, Khetrapal CL. Differential protonation and dynamic structure of doxylamine succinate in solution using 1H and 13C NMR. Magn Reson Chem. 2004 Jul;42(7):636-40. PubMed PMID: 15181634. 8: Pelser A, Müller DG, du Plessis J, du Preez JL, Goosen C. Comparative pharmacokinetics of single doses of doxylamine succinate following intranasal, oral and intravenous administration in rats. Biopharm Drug Dispos. 2002 Sep;23(6):239-44. PubMed PMID: 12214324. 9: Bookstaff RC, Murphy VA, Skare JA, Minnema D, Sanzgiri U, Parkinson A. Effects of doxylamine succinate on thyroid hormone balance and enzyme induction in mice. Toxicol Appl Pharmacol. 1996 Dec;141(2):584-94. PubMed PMID: 8975784. 10: Eccles R, Van Cauwenberge P, Tetzloff W, Borum P. A clinical study to evaluate the efficacy of the antihistamine doxylamine succinate in the relief of runny nose and sneezing associated with upper respiratory tract infection. J Pharm Pharmacol. 1995 Dec;47(12A):990-3. PubMed PMID: 8932681. 11: Skare JA, Murphy VA, Bookstaff RC, Thompson GA, Heise MA, Horowitz ZD, Powell JH, Parkinson A, St Peter JV. Safety assessment of OTC drugs: doxylamine succinate. Arch Toxicol Suppl. 1995;17:326-40. Review. PubMed PMID: 7786169. 12: Slikker W Jr, Holder CL, Lipe GW, Korfmacher WA, Thompson HC Jr, Bailey JR. Metabolism of 14C-labeled doxylamine succinate (Bendectin) in the rhesus monkey (Macaca mulatta). J Anal Toxicol. 1986 May-Jun;10(3):87-92. PubMed PMID: 2873269. 13: Thompson HC Jr, Holder CL, Bowman MC. Trace analysis of doxylamine succinate in animal feed, human, urine, and wastewater by GC using a rubidium-sensitized nitrogen detector. J Chromatogr Sci. 1982 Aug;20(8):373-80. PubMed PMID: 6126486. 14: Legler F, Jansen W. [Double-blind long-term study on a combination of tetracycline, theophylline, doxylamine succinate, etafedrine, phenylephedrine and guaifenesine in chronic bronchitis (author's transl)]. Arzneimittelforschung. 1977;27(4):883-8. German. PubMed PMID: 326265. 15: CANY J, HUIDOBRO H. [Clinical and experimental study of the antihistaminic activity of doxylamine succinate]. Therapie. 1960;15:159-67. French. PubMed PMID: 13807505. 16: Ventura-Gayete JF, de la Guardia M, Garrigues S. On-line sample treatment and FT-IR determination of doxylamine succinate in pharmaceuticals. Talanta. 2006 Dec 15;70(5):1100-6. doi: 10.1016/j.talanta.2006.02.023. Epub 2006 Mar 20. PubMed PMID: 18970887. 17: Pathak A, Rajput SJ. Simultaneous derivative spectrophotometric analysis of doxylamine succinate, pyridoxine hydrochloride and folic Acid in combined dosage forms. Indian J Pharm Sci. 2008 Jul-Aug;70(4):513-7. doi: 10.4103/0250-474X.44607. PubMed PMID: 20046784; PubMed Central PMCID: PMC2792541. 18: Mizoguchi H, Wilson A, Jerdack GR, Hull JD, Goodale M, Grender JM, Tyler BA. Efficacy of a single evening dose of syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. Int J Clin Pharmacol Ther. 2007 Apr;45(4):230-6. PubMed PMID: 17474541. 19: Lee YD, Lee ST. Acute pancreatitis and acute renal failure complicating doxylamine succinate intoxication. Vet Hum Toxicol. 2002 Jun;44(3):165-6. PubMed PMID: 12046971. 20: Argekar AP, Sawant JG. Simultaneous determination of pyridoxine hydrochloride and doxylamine succinate from tablets by ion pair reversed-phase high-performance liquid chromatography (RP-HPLC). Drug Dev Ind Pharm. 1999 Aug;25(8):945-50. PubMed PMID: 10434138.